BiotechTube
Home/Nuvalent/Henry Pelish, PhD
HP

Henry Pelish, PhD

Chief Scientific Officer

Nuvalent

Therapeutic Areas

OncologyPrecision Medicine

Nuvalent Pipeline

DrugIndicationPhase
Zidesamtinib (NVL-520)TKI pre-treated advanced ROS1+ NSCLCPhase 2
Neladalkib (NVL-655)TKI pre-treated advanced ALK+ NSCLCPhase 2
NVL-330Advanced HER2-altered NSCLCPhase 1

Leadership Team at Nuvalent

JP
James Porter, PhD
Chief Executive Officer
AB
Alex Balcom, MBA, CPA
Chief Financial Officer
CT
Christopher Turner, MD
Chief Medical Officer
View full Nuvalent profile